NCT07810829Not yet recruiting
Prognostic Value of CAR, AFR and Ferritin in Non-M3 AML
The Prognostic Significance of C-Reactive Protein to Albumin Ratio, Albumin to Fibrinogen Ratio, and Serum Ferritin Level in Newly Diagnosed De Novo Non-M3 Acute Myeloid Leukemia Patients
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
This prospective cohort study aims to evaluate the prognostic significance of the C-reactive protein-to-albumin ratio (CAR), albumin-to-fibrinogen ratio (AFR), and serum ferritin level in newly diagnosed de novo non-M3 acute myeloid leukemia patients at Assiut University Hospitals.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 208 (estimated)
- First submitted
- 1 Sept 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- Assiut University
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07810829
What you commit to
- Study type: Observational
- Planned participants: 208
- From 1 Sept 2026 to the primary completion date, 1 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous blood transfusions
- Previous exposure to chemotherapy or radiotherapy
Other illness
- Significant cardiac, hepatic, or renal disease
- Diabetes mellitus with polyneuropathy
- History of MDS transformed to AML
Other
- \- Patient refusal
- Severe organ dysfunction (modified Marshall score ≥ 2)
- Relapsed AML
Who the study is looking for
- Age 18 to 65 years
- Newly diagnosed de novo non-M3 acute myeloid leukemia
- Both sexes
- Willingness to provide informed consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.